Sections
You are here: Home Heat-stable ritonavir tablet may be available next year
 
Document Actions

Heat-stable ritonavir tablet may be available next year

A new developmental 100 mg tablet version of the protease inhibitor ritonavir (Norvir) which will not require refrigeration is now in late stage development. It appears to be equivalent to the current soft-gel capsule formulation in terms of side-effects and potency.

Ritonavir is predominantly used as a booster for other protease inhibitors. Ritonavir’s manufacturer Abbott will seek approval for the drug later this year. 

 
Powered by Plone CMS, the Open Source Content Management System

This site conforms to the following standards: